Complete response of Ctnnb1-mutated tumours to b-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model

Journal of Hepatology

Volumn 62, Issue 2, 2015, Pages 380-387

  Delgado, Evan ^a   Okabe, Hirohisa ^a   Preziosi, Morgan ^a   Russell, Jacquelyn Olivia ^a   Alvarado, Tamara Feliciano ^a   Oertel, Michael ^a   Nejak Bowen, Kari Nichole ^a   Zhang, Yixian ^b   Monga, Satdarshan P S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Enzon Incorporated   (United States)

Author keywords

Hepatocellular cancer; Molecular therapy; Mutations; Oncogene; Targeted therapy; Wnt signalling

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CTNNB1 PROTEIN; DIETHYLNITROSAMINE; EZN 3046; EZN 3892; LOCKED NUCLEIC ACID; PHENOBARBITAL; PROTEIN; UNCLASSIFIED DRUG; ALKYLATING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; CTNNB1 PROTEIN, MOUSE; DNA; OLIGONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; ARTICLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; ANIMAL; C3H MOUSE; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS, EXPERIMENTAL; METABOLISM; MUTATION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ALKYLATING AGENTS; ANIMALS; BETA CATENIN; BLOTTING, WESTERN; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; DIETHYLNITROSAMINE; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXCITATORY AMINO ACID ANTAGONISTS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C3H; MUTATION; OLIGONUCLEOTIDES; PHENOBARBITAL; TUMOR CELLS, CULTURED;

EID: 84922243359     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.10.021     Document Type: Article

References (42)

1. Aydinlik H, Nguyen TD, Moennikes O, Buchmann A, Schwarz M. Selective pressure during tumour promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumours. Oncogene 2001; 20: 7812-7816.
2. Behari J, Zeng G, Otruba W, Thompson MD, Muller P, Micsenyi A, et al. REtodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells. J Hepatol 2007; 46: 849-857.
3. Braeuning A, Heubach Y, Knorpp T, Kowalik MA, Templin M, Columbano A, et al. Gender-specific interplay of signaling through beta-catenin and CAR in the regulation of xenobiotic-induced hepatocyte proliferation. Toxicol Sci 2011; 123: 113-122.
4. Cadoret A, Ovejero C, Terris B, Souil E, Levy L, Lamers WH, et al. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 2002; 21: 8293-8301.
5. Cheng JH, She H, Han YP, Wang J, Xiong S, Asahina K, et al. Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2008; 294: G39-G49.
6. Chiu M, Tardito S, Pillozzi S, Arcangeli A, Armento A, Uggeri J, et al. Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts. Br J Cancer 2014; 111(6): 1159-1167.
7. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998; 95: 8847-8851.
8. Delgado E, Bahal R, Yang J, Lee JM, Ly DH, Monga SP. Beta-catenin knockdown in liver tumour cells by a cell permeable gamma guanidinebased peptide nucleic acid. Curr Cancer Drug Targets 2013; 13(8): 867-878.
9. Delgado ER, Yang J, So J, Leimgruber S, Kahn M, Ishitani T, et al. Identification and characterization of a novel small-molecule inhibitor of beta-catenin signaling. Am J Pathol 2014; 184: 2111-2122.
10. Elayadi AN, Braasch DA, Corey DR. Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry 2002; 41: 9973-9981.
11. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A 2004; 101: 12682-12687.
12. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 2006; 6: 674-687.
13. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
14. Fluiter K, ten Asbroek AL, de Wissel MB, Jakobs ME, Wissenbach M, Olsson H, et al. In vivo tumour growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Res 2003; 31: 953-962.
15. Gebhardt R, Mecke D. Heterogeneous distribution of glutamine synthetase among rat liver parenchymal cells in situ and in primary culture. EMBO J 1983; 2: 567-570.
16. Gougelet A, Torre C, Veber P, Sartor C, Bachelot L, Denechaud PD, et al. T-cell factor 4 and beta-catenin chromatin occupancies pattern zonal liver metabolism in mice. Hepatology 2014; 59: 2344-2357.
17. Kawamoto T, Sueyoshi T, Zelko I, Moore R, Washburn K, Negishi M. Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol 1999; 19: 6318-6322.
18. Kumar R, Singh SK, Koshkin AA, Rajwanshi VK, Meldgaard M, Wengel J. The first analogues of LNA (locked nucleic acids): Phosphorothioate-LNA and 20-thio-LNA. Bioorg Med Chem Lett 1998; 8: 2219-2222.
19. Lee JM, Yang J, Newell P, Singh S, Parwani A, Friedman SL, et al. Beta-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation. Cancer Lett 2014; 343: 90-97.
20. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
21. Loeppen S, Koehle C, Buchmann A, Schwarz M. A beta-catenin-dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumours. Carcinogenesis 2005; 26: 239-248.
22. Loeppen S, Schneider D, Gaunitz F, Gebhardt R, Kurek R, Buchmann A, et al. Overexpression of glutamine synthetase is associated with beta-cateninmutations in mouse liver tumours during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res 2002; 62: 5685-5688.
23. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013; 4: 2218.
24. Nault JC, Zucman-Rossi J. Genetics of hepatocellular carcinoma: The next generation. J Hepatol 2014; 60: 224-226.
25. Nejak-Bowen KN, Monga SP. Beta-catenin signaling, liver regeneration and hepatocellular cancer: Sorting the good from the bad. Semin Cancer Biol 2011; 21: 44-58.
26. Okabe H, Delgado E, Lee JM, Yang J, Kinoshita H, Hayashi H, et al. Role of leukocyte cell-derived chemotaxin 2 as a biomarker in hepatocellular carcinoma. PLoS One 2014; 9: E98817.
27. Petersen M, Bondensgaard K, Wengel J, Jacobsen JP. Locked nucleic acid (LNA) recognition of RNA: NMR solution structures of LNA: RNA hybrids. J Am Chem Soc 2002; 124: 5974-5982.
28. Santos NP, Pereira IC, Pires MJ, Lopes C, Andrade R, Oliveira MM, et al. Histology, bioenergetics and oxidative stress in mouse liver exposed to Ndiethylnitrosamine. In vivo 2012; 26: 921-929.
29. Schmid A, Rignall B, Pichler BJ, Schwarz M. Quantitative analysis of the growth kinetics of chemically induced mouse liver tumours by magnetic resonance imaging. Toxicol Sci 2012; 126: 52-59.
30. Singh Y, Port J, Schwarz M, Braeuning A. Genetic ablation of beta-catenin inhibits the proliferative phenotype of mouse liver adenomas. Br J Cancer 2014; 111: 132-138.
31. Stenvang J, Silahtaroglu AN, Lindow M, Elmen J, Kauppinen S. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin Cancer Biol 2008; 18: 89-102.
32. Tan X, Behari J, Cieply B, Michalopoulos GK, Monga SP. Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology 2006; 131: 1561-1572.
33. Tardito S, Chiu M, Uggeri J, Zerbini A, Da Ros F, Dall'Asta V, et al. LAsparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of beta-catenin-mutated human hepatocellular carcinoma cells. Curr Cancer Drug Targets 2011; 11: 929-943.
34. Thompson MD, Dar MJ, Monga SP. Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of beta-catenin. J Hepatol 2011; 54: 506-512.
35. Unterberger EB, Eichner J, Wrzodek C, Lempiainen H, Luisier R, Terranova R, et al. Ha-ras and beta-catenin oncoproteins orchestrate metabolic programs in mouse liver tumours. Int J Cancer 2014; 135: 1574-1585.
36. Wahlestedt C, Salmi P, Good L, Kela J, Johnsson T, Hokfelt T, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A 2000; 97: 5633-5638.
37. Wei W, Chua MS, Grepper S, So S. Small molecule antagonists of Tcf4/betacatenin complex inhibit the growth of HCC cells in vitro and in vivo. Int J Cancer 2010; 126: 2426-2436.
38. Wickline ED, Awuah PK, Behari J, Ross M, Stolz DB, Monga SP. Hepatocyte gamma-catenin compensates for conditionally deleted beta-catenin at adherens junctions. J Hepatol 2011; 55: 1256-1262.
39. Wickline ED, Du Y, Stolz DB, Kahn M, Monga SP. Gamma-Catenin at adherens junctions: Mechanism and biologic implications in hepatocellular cancer after beta-catenin knockdown. Neoplasia 2013; 15: 421-434.
40. Wise DR, Thompson CB. Glutamine addiction: A new therapeutic target in cancer. Trends Biochem Sci 2010; 35: 427-433.
41. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010; 7: 448-458.
42. Zeng G, Apte U, Cieply B, Singh S, Monga SP. SiRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia 2007; 9: 951-959.